The COVID-19 pandemic accelerated the adoption of point-of-care molecular technologies that offer quick sample to results, high sensitivity, lower cost and widespread accessibility.

This webinar will cover new market-leading reagent solutions for loop-mediated isothermal amplification (LAMP) assays, which simplify assay development, speed up assay turnaround time, and deliver highly sensitive and specific amplification without DNA or RNA extraction.

Presenters
Elda Iljazi Ph.D.
Senior Scientist Meridian Bioscience

Molecular point of care (POC) tests are rapidly gaining traction in the diagnostic market, especially for infectious diseases. While LAMP and qPCR testing share common advantages such as quick turnaround time and high sensitivity and specificity, LAMP has additional benefits, making it possible for testing to be carried out essentially anywhere – from an airport to school, to a remote medical clinic.

In this webinar you will learn about:

• The new advances in the LAMP and qPCR assay development for POC
• How to speed up sample-to-result and eliminate the need for cold-chain management

Speakers:
Elda Iljazi, Ph.D. – R&D Senior Scientist, Meridian Bioscience
Dr. Michele Amasio – Research and Development Manager

Despite gaining traction in diagnostics, molecular Point-of-Care (POC) tests face challenges related to accessibility, stability, and ease of workflow.

Due to infrastructure limitations, especially in remote areas, there is often a lack of necessary resources for appropriately storing reagents, and complex workflows are frequently difficult to implement in non-laboratory settings.

VIEW THIS WEBINAR TO LEARN ABOUT:

• Innovative molecular reagents that simplify assay workflow using direct detection
• Benefits to eliminating cold-chain through ambient temperature assay stability
• Advances in qPCR and isothermal technologies tailored for point-of-care use

Don’t miss this opportunity to gain valuable insights from experts in molecular reagent development.

As precision medicine in oncology advances, selecting the right genomic analysis method is key to obtaining accurate and actionable insights. Whether detecting MRD, identifying mutations, or developing liquid biopsy assays, the choice between qPCR, targeted NGS, and whole-genome sequencing directly impacts clinical utility.

Speaker: Dale Clash, Strategic Marketing Manager (Molecular)

VIEW THIS WEBINAR TO LEARN ABOUT:

• How qPCR, targeted NGS, and whole-genome sequencing compare in precision medicine applications such as liquid biopsy, MRD monitoring, mutation detection, and hereditary disease screening.
• The advantages and limitations of each approach, including key considerations for
  sensitivity, throughput, cost, and data requirements.
• Real-world assay examples demonstrating how these technologies are applied in
  clinical oncology settings.

Join us to gain a deeper understanding of these powerful technologies and how Meridian can support your assay development with innovative solutions tailored to your needs.